Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago.
ANI Pharmaceuticals: A Short-Term Buying Opportunity
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Growth Investors Will Love ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI.
4 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
